Paxil CR In Recovery, But Still Hobbling GSK’s U.S. Rx Sales Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
Controlled-release paroxetine recaptures 41% of pre-seizure new prescription share, but the sales interruption still slows growth of GSK’s U.S. pharma business during the second quarter.